Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest

Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer. The companies’ oral drug, called zipalertinib, plus ...